Company adds Lukas Scheibler as Chief Science and Technology Officer STUART, Fla. , July 25, 2024 /PRNewswire/ -- Stuart Therapeutics, a clinical-stage ophthalmic biopharmaceutical company focused on developing therapies for the treatment of anterior segment, refractive and posterior segment eye disorders, today announced the addition of Lukas Scheibler , PhD as its Chief Science and Technology Officer. "The advancement of our pipeline of novel collagen mimetic peptide therapeutics has increased the need for us to augment our capabilities.
We are excited to have Lukas join the Stuart Therapeutics team as our Chief Science and Technology Officer. He has an extensive background in pharma, and we are particularly excited about his capabilities in retinal indications, an area where Stuart has developed some very exciting pre-clinical results. Lukas will work with a strong research team that includes Brian Del Buono , PhD, EVP R&D, and David Calkins , PhD.
Dr. Calkins who has acted as the company's Chief Science Officer, will take on the new role as the head of our Scientific Advisory Board" said Eric Schlumpf , Stuart's President and CEO. "Stuart Therapeutics is developing an extremely interesting therapeutic platform that targets diseased tissues in a novel way compared to conventional therapeutics for ophthalmology," said Dr.
Scheibler. "The company has demonstrated the ability to build viable development programs with a lean, effective team. I'm pleased to be a part of this st.